Deep Transcranial Magnetic Stimulation (DTMS) as a Treatment for Attention Deficit Hyperactivity Disorder (ADHD) in Adults

Attention Deficit Hyperactivity Disorder Clinical Trial

Official title:

Test Efficiency of Deep Transcranial Magnetic Stimulation (DTMS) Using an H-coil for Dorso-Lateral Prefrontal Cortex (HLPFC) to Treat Attention Deficit Hyperactivity Disorder (ADHD) in Adults

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT01196910
• Other study ID #: IBR-0014-00
• Status: Recruiting
• Phase: Phase 1
• Start date: July 2011
• Est. completion date: September 2020

Study information

• Verified date: January 2020
• Source: Brainsway
• Contact: Elissa Ash, Dr.
• Phone: +972-3-6973328
• Email: elissaa[@]tasmc.health.gov.il
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aim of the study is to assess the effect of left or right high-frequency DTMS on ADHD symptoms, cognitive performance and decision-making ability of ADHD adults, and to compare this to the effect of sham DTMS on ADHD adults

Description:

Attention deficit disorder in adults may be due to hypoactivity of prefrontal areas of the brain. Increasing the activity of these areas may help improve symptoms in many of these patients. In addition there is evidence as to dysfunction in both hemispheres of the brain, but it is difficult to determine the contribution of each hemisphere's pattern of activity to behavioral impairment. The purpose of this study is to use high-frequency DTMS to stimulate activity either on the left side of the prefrontal cortex (one arm), or on the right side (a second arm), to see if such stimulation improves attention, comparing to sham DTMS simulation (a third arm).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 45
• Est. completion date: September 2020
• Est. primary completion date: September 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Men and women aged 18-65.

• Appropriate diagnosis of ADHD according to DSM-IV criteria:

o DSM-IV criteria require not only that the ADHD symptoms be present now (self-report), but also to have been present in childhood (self-report)

• Subjects taking medications for attention deficit disorder will give their consent to stop the drugs from a week before the start of participation in the study, and during the daily treatment phase (four weeks total); subjects also will be asked not to take these medications 24 hours before participation in the review meetings (4 and 8 weeks after the end of the daily treatment phase).

• Subjects have given their written and oral consent to participate in research.

Exclusion Criteria:

• Any DSM-IV Axis I psychiatric disorder.

• Use of antipsychotic stabilizers; other than benzodiazepines if necessary to a daily dosage equivalent to 2 mg Lorazepam.

• History of lack of tolerance to TMS.

• Diagnosis of severe DSM-IV personality disorder.

• Current suicidal tendency.

• Uncontrolled high blood pressure

• History of epilepsy, seizures or fever convulsions.

• History of epilepsy or convulsions in first-degree relatives.

• A history of head injury or a stroke which caused deficits.

• History of metal in the head (outside the oral cavity).

• History of plastic or metal implants, including metallic particles in the eye, pacemaker, implanted hearing aid devices, use of neurostimulators, or any medical pump.

• A history of drug or alcohol misuse.

• People who lack judgment or are unable to communicate with the experimenters.

• Participation in any other medical research during the three months prior to the time of this experiment.

• Subject's inability to sign a consent form.

• Pregnancy, or not using contraception.

Related Conditions & MeSH terms

• Attention Deficit Disorder with Hyperactivity
• Attention Deficit Hyperactivity Disorder
• Hyperkinesis

Intervention

Device:
• treatment by HLPFC coil
DTMS treatment will be given for 3 weeks, 5 days a week. Before each DTMS treatment, neural network excitation practice will be done using AttenGo software (AttenGo, Herzlia, Israel). Each treatment day: Follow-up to evaluate clinical side effects of treatment. Two additional meetings with DTMS treatment and follow-up will be held to evaluate the efficacy of treatment and side effects. The first will be four weeks after the end of the daily treatment phase; the second eight weeks after the end of the daily treatment phase.

Locations

Country	Name	City	State
Israel	Tel-Aviv Sourasky Medical Center	Tel-Aviv

Sponsors (1)

Lead Sponsor	Collaborator
Brainsway

Country where clinical trial is conducted

Israel, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Conners' Adult ADHD Rating Scale		Screening, at the end of three weeks of treatment, and for each of two follow-up meetings
Secondary	Mindstreams Cognitive Tests		Screening, at the end of three weeks of treatment, and for each of two follow-up meetings